Ciloa will be presenting its disrupting co-agonist, Adiponectin, that boosts all GLP-1RA therapeutic effects on obesity/diabetes/MASH @Swiss Biotech Days 2024 (Basel, April 22-23)

Ciloa, a preclinical stage French biotechnology company with a unique exosome bioengineering technology will attend the SwissBiotechDay 2024.

Ciloa will be presenting its disrupting co-agonist, Adiponectin, that boosts all GLP-1RA therapeutic effects on obesity/diabetes/MASH.

Attend Ciloa’s presentation on April Tuesday 24th at 4PM in Osaka room, or meet us at the French “MRGN” booth in the Global village.

The Swiss Biotech Day is a premier biotechnology conference in Europe, attracting professionals from the global life sciences community. In 2024, it will once again provide a platform for networking, engaging discussions, and the exploration of advancements in R&D, manufacturing, data management, artificial intelligence, and innovative financing.